【作者】 梅雪婷； 苏畅； 许东晖；

【Author】 MEI Xue-ting, SU Chang, XU Dong-hui* (Lab. of Chinese Medicine and Marine Drugs, School of Life Sciences, Sun Yat-sen University, Guangzhou 510275)

【机构】 中山大学生命科学学院中药与海洋药物研究室；

【摘要】 利用茶叶中含量最丰富、活性最强的表没食子儿茶素没食子酸酯(EGCG)与锌离子配位健结合制成的新化合物EGCG-Zn,开展其对实验性肝损伤的药理作用研究。通过对人肝星状细胞(HSC)增殖的抑制作用和CCL4致大鼠慢性肝纤维化模型评价新化合物EGCG-Zn对实验性肝纤维化的药理作用,表明:EGCG-Zn能够明显抑制肝星状细胞的增殖,促进其凋亡,对肝纤维化具有抑制作用;EGCG-Zn能够明显降低肝纤维化大鼠的血清Hyp、ALT、ALP、TB、TP、Alb含量以及A/G比例,提高肝匀浆CAT、GSH-Px、GST等抗氧化酶活性,抑制肝组织TGF-β1蛋白的表达,从而达到抑制肝纤维化的发生及发展,发挥EGCG与锌离子的协同作用,产生比EGCG更强的药理作用。更多还原

【Abstract】 A new compound EGCG-Zn was synthesized by epigallocatechin-3-gallate (EGCG) and zinc was tested its pharmacologied by Ccts on anti-liver fibrosis through inhibiting human HSC cell proliferation and rat chronic liver fibrosis induced by CCL4. The results showed that EGCG-Zn can obviously inhibit proliferation of HSC cell and liver fibrosis, promate its apoptosis. EGCG-Zn also can obviously reduce content of Hyp, ALT, ALP, TB, TP, Alb and ratio of A/G, improving activities of CAT, GSH-Px and GST, inhibit the expression of TGF-β? and the happen and development of liver fibrosis to show high pharmacological effects than EGCG, indicating a synergistic effect of EGCG and Zinc.更多还原